3 Suzhou Dongshan Precision Manufacturing Co.Ltd(002384) 14 released the annual performance report of 2021, and the company achieved an annual operating revenue of 489 million yuan, an increase of 11.91% year-on-year; The net profit attributable to the shareholders of the listed company was 73.687 million yuan, a year-on-year increase of 58.14%; The basic earnings per share was 0.28 yuan, a year-on-year increase of 55.56%.
The biomaterials sector achieved an operating revenue of 305 million yuan, an overall increase of 25.51% over 2020. Among them, guanlang, a new generation meningeal product, increased by 53.13% over the same period last year; The repair membrane of thoracic general surgery increased by 48.26% year-on-year. In addition, the German intracranial pressure monitoring products represented by the company have adhered to academic promotion and standardized application for several years, and maintained a high-speed growth of 51.75% in 2021. With the increasing number of users, it has laid a good foundation for the continuous growth in 2022. By continuously enriching the product line, the brand influence of the company in the Chinese market has been further improved.
It is worth noting that the company’s pharmaceutical product benvemod cream sold in large quantities in 2021, realizing an operating revenue of 299274 million yuan. It is understood that the drug was approved with a new drug certificate in May 2019, bringing new hope to the majority of psoriasis patients. At present, benvemod cream has been officially included in the national medical insurance catalogue and implemented. The inclusion of benvemod cream in medical insurance will benefit more patients. The sales volume of this product will be 100000 in 2020 and nearly 400000 in 2021. In the future, with the acceleration of hospital opening and the further strengthening of medical and patient academic education and promotion activities, the pharmaceutical sector will have a positive impact on the company’s operating performance.
In addition, the company’s cell sector achieved an operating revenue of 248483 million yuan, a year-on-year increase of 24.46%, and achieved a double harvest of economic and social benefits. Further integrate and optimize the internal organizational structure, the survival of the fittest mechanism to maximize resource allocation, and the performance of the sector has increased steadily for three consecutive years.
